Dr. Hyo S. Han, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 85
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME101448 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- H Lee Moffitt Cancer Ctr and Res Inst Life Time Cancer Scrn Ctr Inc (1,178 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 85
- Services billed
- 223
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 109 | 51 |
| Established patient office or other outpatient visit, 30-39 minutes | 55 | 47 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Tampa, FL | 73 |
| Letrozole Other prescribers in Tampa, FL | 55 |
| Ibrance (palbociclib) | 34 |
| Exemestane | 24 |
| Truqap (capivasertib) | 23 |
| Verzenio (abemaciclib) | 22 |
| Tamoxifen Citrate Other prescribers in Tampa, FL | 12 |
| Ondansetron Hcl Other prescribers in Tampa, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 12 payments worth $5,085 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $2,347 |
|---|---|
| Pfizer Inc. | $2,268 |
| Lilly USA, LLC | $229 |
| Stemline Therapeutics Inc. | $154 |
| Gilead Sciences, Inc. | $86.17 |
| Consulting Fee | $4,305 |
|---|---|
| Food and Beverage | $780 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Mar 7, 2025 | Consulting Fee KISQALI · Oncology | $2,100 |
| Pfizer Inc. Jun 13, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $1,260 |
| Pfizer Inc. Jan 13, 2025 | Consulting Fee PAXLOVID · INFECTIOUS DISEASES | $945 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $697,950 in research payments for these studies, mostly to the institutions running them.
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors
Exelixis Inc. - Tactiveu an interventional safety and efficacy phase 1B2 openlabel umbrella study to investigate tolerability pk and antitumor activity of ARV471 PF07850327 an oral proteolysis targeting chimera in combination with ot…
Pfizer Inc. - A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
Genentech, Inc. - I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Jazz Pharmaceuticals Inc. - Tactiveu an interventional safety and efficacy phase 1B2 openlabel umbrella study to investigate tolerability pk and antitumor activity of ARV471 PF07850327 an oral proteolysis targeting chimera in combination with ot…
Pfizer Inc. - Single arm open label phase 1B2 study of SGNLIV1A in combination with pembrolizumab for firstline treatment of patients with unresectable locallyadvanced or metastatic triplenegative breast cancer
Pfizer Inc. - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT01042379 - PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial
Jazz Pharmaceuticals Inc. - Tactiveu an interventional safety and efficacy phase 1B2 openlabel umbrella study to investigate tolerability pk and antitumor activity of vepdegestrant ARV471PF07850327 an oral proteolysis targeting chimera in combin…
Pfizer Inc. - Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.